Prestige Biologics (334970) 🔎 In-depth
KOSDAQ · Price as of 2026-08-06 · Updated 2026-08-09
Prestige Biologics is a contract development and manufacturing (CDMO) company that makes medicines on behalf of other pharmaceutical and biotech firms; with large-scale production facilities for antibody drugs, it earns revenue by producing client volumes, so its results hinge heavily on securing production contracts and keeping the plant utilized. Recently it has been at the early stage of growth as revenue expands more than fourfold, with supply contracts continuing — ₩2.7 billion in June (21.3% of recent revenue) and ₩2.4 billion in May (19.1%) — though April also brought a contract-termination disclosure. What stands out is that in a phase where client production volumes keep filling up and rising revenue converts into a profit, the undemanding valuation of a 1.12x P/B is a strength; but it weakens if contracts prove one-off or utilization is slow, and if the operating margin of -268.7% and the funding strain of a 39.9% current ratio grow.
This page organises public market and filing data for information purposes. It is not a recommendation to buy or sell, nor investment advice. Metrics labelled “forward” are our own unverified estimates. Please verify with the original DART filings and decide at your own responsibility.
30-second brief
Pulled directly from the computed values below — not a separately written opinion.
What do the SourceComputedEstimateReading tags mean?
Source filings and exchange data · Computed calculated from public data · Estimate our own unverified projection · Reading drafted automatically, then rule-checked. See AI & Automation.
Core valuation metric
This stock's effective sub-sector is “CDMO & Biosimilars” (Biotech & Pharmaceuticals), a type typically read first through forward P/E.
CDMO and biosimilar players see future utilization and profit hinge on large capacity build-outs and new supply contracts. Because it is the earnings still to come — reflecting fresh orders and added capacity — that drives the price, forward P/E, based on expected earnings, is the first lens.
Price against earnings alone becomes unstable when earnings swing. Reading it together with price against assets helps gauge the downside.
That said, the company is currently in a revenue-growth rather than a profit phase, so this metric alone offers only a limited read.
This note explains how each sector is typically valued and is educational context only, not investment advice.
At-a-glance assessment financial health · growth · profitability · valuation
- Assets that can be turned to cash within a year fall short of near-term liabilities (current ratio 44.6%).
- The most recent full-year net result was a loss.
- Revenue rose 477.8% year over year, and the pace is quickening (3-year trend: rising).
- Most recent quarter (Q3 2025) revenue was 444.9% higher than a year earlier.
- ROE is -20.3% (total-net basis). It is below the sector average.
- Operating margin is -268.7%.
- A sector-metric and in-depth research verdict — see “Valuation vs peers” below for the basis.
Ownership & governance As of 2025-06-30
Largest shareholder Prestige Biopharma 40.03% (individual)
Controlling bloc incl. related parties 60.22%
With the controlling bloc holding 60%, control is very secure but the free float is thin.
🔎 In-depth analysis Reading
Prestige Biologics is not a company that makes and sells biopharmaceuticals directly; instead it runs a contract development and manufacturing (CDMO) business, producing medicines on behalf of other pharmaceutical and biotech firms. In other words, it holds large-scale production facilities (culture and purification processes) capable of making biologic products such as antibody drugs, and it earns revenue by producing the volumes entrusted by clients. Its results therefore hinge heavily on 'how many production contracts it wins and how full it keeps the plant.' Because the market capitalization is not large, one must watch not only the business itself but also how each production-contract disclosure affects revenue and the finances.
The latest close is ₩1,939 and the market capitalization is ₩150.8 billion. The price sits above its 20-day moving average (₩1,819) and above its 60-day moving average (₩1,901). It holds above both its short- and medium-term moving averages, so the trend looks healthy. The RSI (a supplementary indicator that gauges the strength of gains versus losses over the past 14 days on a 0-100 scale) is 56.6, a neutral level. The one-month change is +2.5%, the three-month change is -9.2%, and the position relative to the 52-week high is -50.5%. Relative strength versus the KOSDAQ is 53 (on a 1-99 scale, converted from returns against the index over the past year with more weight on recent performance; higher means stronger than the market). It is stronger than roughly 53% of all stocks. Over the past three months it outpaced the index by 38.1%. Chart interpretation is best done alongside trading volume and the dates on which disclosures occur.
Recent annual revenue was ₩12.5 billion, operating profit -₩33.7 billion and net profit -₩27.5 billion — still a loss. The operating margin is -268.7%, ROE (how much is earned in a year on equity) is -20.3%, and the debt-to-equity ratio is 99.9%. The P/E ratio (how many times a year's profit the share price represents) is not calculable because earnings are negative, and the P/B (how many times book value the share price represents) is 1.13x. This P/B is not markedly high even against the adjacent peer set (Dong Wha Pharm 0.35x, Hi-Tech Pharm 1.03x, Samsung Pharm 0.99x), so on a book-value basis the share price is not richly valued. That said, with fewer assets readily convertible to cash than debt due within a year (a current ratio of 39.9%), short-term funding capacity is on the tight side — an area to confirm alongside an earnings recovery.
The revenue trajectory is the core change at this company. Revenue jumped from ₩1.7 billion in 2023 and ₩2.2 billion in 2024 to ₩12.5 billion in 2025, up 477.8% year on year, and the pace of increase is accelerating (a rising three-year trend). In the most recent quarter, the third quarter of 2025, revenue of ₩3.5 billion was also up 444.9% from the same period a year earlier. In contract manufacturing, revenue is recognized in earnest once client volumes translate into actual plant operation after the facilities are in place, and this looks like the early stage of that ramp-up. Even as revenue rises quickly, however, operating profit (-₩33.7 billion) and net profit (-₩27.5 billion) are still losses, and the timing of the turn to profit — when rising revenue overtakes costs and becomes profit — is hard to pin down because the company has not issued a numerical forecast (official guidance). For that reason, no forward metric gauging this year's profit is shown, as there is no basis to compute one — rather than inserting a figure that does not exist, it is more accurate to confirm quarter by quarter whether revenue growth flows through to profit.
Recent disclosures center on production contracts. On 2026-06-10 a single sale and supply contract (₩2.7 billion, 21.3% of recent revenue) and on 2026-05-15 a single sale and supply contract (₩2.4 billion, 19.1%) continued a run of contracts meaningful to the revenue base. On 2026-04-30, by contrast, there was a disclosure terminating a single sale and supply contract, so the detailed terms in the source text need to be checked. As a contract manufacturer, whether these contracts are one-time transactions or recurring volumes shapes the medium-term revenue picture. The contract amounts and terms can be confirmed in each disclosure's source text.
The strong side and the side to watch are clearly divided. The strengths are that it is at the early stage of growth, with revenue expanding more than fourfold as contract-manufacturing volume rises and the pace quickening, and that the share price against book value (a 1.12x P/B) is not expensive relative to peers. On the other side, points to confirm are that revenue has not yet converted into profit so losses continue (operating margin -268.7%), that short-term funding capacity is tight (current ratio 39.9%), and that the stability of contracts — as with the April termination — can shake the results. In short, this company is strong in a 'phase where client production volumes keep filling up and rising revenue links to profit,' and weak in a 'phase where contracts prove one-off, utilization is slow, and the funding strain grows.' The direction of growth is clear, but it is a stock to watch alongside whether that growth settles into profit and cash.
🔎 Valuation vs peers Undervalued
A peer set within pharma and bio with adjacent market capitalization.
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Dong Wha Pharm | 16.11x | 0.36x | 2.29% |
| Hitech Pharm | 10.23x | 0.91x | 8.78% |
| Samsung Pharm | 10.69x | 0.95x | -13.04% |
Within pharma and bio, a public-data peer set with nearby market capitalization was looked at first. The current P/E ratio (how many times a year's profit the share price represents) is not confirmable, and the P/B (how many times book value the share price represents) is 1.13x. That said, smaller-cap names are heavily affected by earnings swings and financing disclosures, so no conclusion was drawn from last year's confirmed-results metrics alone. The forecast box basis is: the company's official outlook is not confirmable.
Price history Close · MA20 · MA60
The latest close is ₩1,939 and the market capitalization is ₩150.8 billion. The price sits above its 20-day moving average (₩1,819) and above its 60-day moving average (₩1,901). It holds above both its short- and medium-term moving averages, so the trend looks healthy. The RSI (a supplementary indicator that gauges the strength of gains versus losses over the past 14 days on a 0-100 scale) is 56.6, a neutral level. The one-month change is +2.5%, the three-month change is -9.2%, and the position relative to the 52-week high is -50.5%. Relative strength versus the KOSDAQ is 53 (on a 1-99 scale, converted from returns against the index over the past year with more weight on recent performance; higher means stronger than the market). It is stronger than roughly 53% of all stocks. Over the past three months it outpaced the index by 38.1%. Chart interpretation is best done alongside trading volume and the dates on which disclosures occur.
Relative performance stock vs index · start = 100
Excess return vs index · 3M +38.12% / 6M -6.95% / 12M -47.75%
Key metrics Computed vs sector median
Valuation
A net loss makes the P/E an unreliable valuation gauge. The P/B of 1.13x is in line with the sector median (1.10x).
Enterprise value (EV)
EV = market cap + net debt. It reflects cash and debt, so it captures the real cost of the whole business that market cap alone misses; lower multiples are cheaper relative to earnings or sales.
Profitability & financials
Return on equity (ROE) is -20.3%, below the sector average (1.0%). The operating margin is -268.7%. The debt ratio is 107.8%, so the financial structure is moderate.
Growth FY2025 · annual report (separate)
| Item | 2023 | 2024 | 2025 | YoY |
|---|---|---|---|---|
| Revenue | $1.2M | $1.5M | $8.8M | +477.83% ↑ faster |
| Operating profit | -$15.5M | -$23.5M | -$23.7M | — |
| Net profit | -$12.6M | -$20.6M | -$19.3M | — |
| 5-year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $2.3M | $10,935 | $1.2M | $1.5M | $8.8M |
| Operating profit | -$18.9M | -$25.7M | -$15.5M | -$23.5M | -$23.7M |
| Net profit | -$27.7M | -$34.9M | -$12.6M | -$20.6M | -$19.3M |
| Revenue CAGR | 4-yr avg 40.39% | ||||
Revenue rose 477.8% year over year (2023 ₩1.7 billion → 2024 ₩2.2 billion → 2025 ₩12.5 billion), and the three-year trend is 'rising'. The pace of growth also quickened from the prior year. Operating results are in the red, so a swing back to profit matters more than the growth rate here. Over the 5 years on record, revenue compound annual growth (CAGR) is 40.4%. The two-year revenue CAGR is 169.1%. In the most recent quarter (Q3 2025), revenue was 444.9% higher than the same period a year earlier.
Latest quarterly results Source Q3 2025 · vs year-ago
Technical indicators Computed
What stands out
- Revenue grew 477.8% year over year, a sign of growth.
Points to watch
- Assets that can be turned to cash within a year fall short of near-term liabilities (current ratio 44.6%).
- The most recent full-year net result was a loss.
- The most recent full year was a loss, so it is worth checking whether profitability recovers.
Recent news & events searched · sourced
- 2026-06-10ContractSingle sale and supply contract signed: contract amount ₩2.7 billion · 21.3% of recent revenueThe contract amount and term are key to future revenue recognition. Whether it is a one-off or a repeatable transaction shapes the medium-term reading. Source
- 2026-05-15ContractSingle sale and supply contract signed: contract amount ₩2.4 billion · 19.1% of recent revenueThe contract amount and term are key to future revenue recognition. Whether it is a one-off or a repeatable transaction shapes the medium-term reading. Source
- 2026-04-30ContractSingle sale and supply contract terminated: confirm detailed terms in the source textThe contract amount and term are key to future revenue recognition. Whether it is a one-off or a repeatable transaction shapes the medium-term reading. Source
Figure cross-check computed ↔ external
| Metric | Computed | External | Status | Source |
|---|---|---|---|---|
| Closing price | ₩1,939 | ₩1,939 | Confirmed | link |
| Latest quarterly results | revenue ₩3.5 billion, operating profit -₩7.3 billion | revenue ₩3.5 billion, operating profit -₩7.3 billion | Confirmed | link |
| Annual results | revenue ₩12.5 billion, operating profit -₩33.7 billion | revenue ₩12.5 billion, operating profit -₩33.7 billion | Confirmed | link |
| Contract disclosure source text | single supply contract signed: contract value ₩2.7 billion · vs recent revenue 21.3% | single supply contract signed: contract value ₩2.7 billion · vs recent revenue 21.3% | Confirmed | link |
| Contract disclosure source text | single supply contract signed: contract value ₩2.4 billion · vs recent revenue 19.1% | single supply contract signed: contract value ₩2.4 billion · vs recent revenue 19.1% | Confirmed | link |
| Contract disclosure source text | single supply contract terminated: see the filing for detailed terms | single supply contract terminated: see the filing for detailed terms | Confirmed | link |
| Forecast box basis | — | — | Unverified | — |
Recent filings Source
- 2026-06-10Single supply/sales contract
- 2026-05-15PeriodicQuarterly report
- 2026-05-15Single supply/sales contract
- 2026-04-30Single supply/sales contract
- 2026-04-30Single supply/sales contract (amended)
- 2026-04-23Disclosure
- 2026-04-02Disclosure
- 2026-03-26Disclosure
- 2026-03-20Disclosure
- 2026-02-13PeriodicSemi-annual report
📖 Plain-language glossary — expand if you are new to this
- P/E
- How many times a year's net profit the price is worth (lower is cheaper relative to earnings). The P/E here is on trailing (last full-year) results; for companies whose earnings swing fast (memory chips and other cyclicals/high-growth), a forward P/E on this year's expected earnings is more accurate.
- P/B
- Price relative to net assets (equity). Around 1x means it trades near book value; below 1x means below book.
- P/S
- Price relative to a year's revenue — useful for growth companies with thin earnings.
- Net debt / EV
- Net debt = interest-bearing debt − cash. Negative means more cash than debt (net cash). EV (enterprise value) = market cap + net debt, closer to what it would cost to buy the whole business.
- EV/EBIT · EV/EBITDA · EV/Sales
- Enterprise value against operating profit (EBIT), EBITDA, or revenue. Unlike P/E these reflect debt and cash; lower is cheaper relative to earnings power or sales.
- FCF / FCF yield
- Free cash flow = operating cash − capex, the cash actually left over. FCF yield = FCF ÷ market cap; higher means more cash generated per unit of market value.
- Intrinsic value (DCF)
- Future free cash flow (or, for some capex-heavy but profitable names, forecast earnings) discounted to today to estimate per-share value. Because it shifts a lot with the discount-rate and growth assumptions, it is shown as a bear/base/bull range, and the basis and assumptions are disclosed in one line beneath it.
- ROE
- How much profit the company earns in a year on its equity (%). Higher means better returns on capital.
- EPS / BPS
- Earnings per share / net assets (book value) per share.
- Operating / net margin
- Profit left from the core business / final profit after tax and interest, per unit of revenue.
- Debt ratio
- Debt relative to equity (%). Higher means more reliance on borrowing (norms vary by sector).
- Current ratio
- Assets convertible to cash within a year against debt due within a year. Above 100% leaves some short-term headroom.
- Interest coverage
- How many times operating profit covers the interest owed. Below 1x means operating profit alone struggles to cover interest.
- Dividend yield / payout ratio
- The year's dividend as a % of today's price / the share of earnings paid out as dividends.
- Revenue CAGR
- Multi-year growth expressed as a single yearly average (compound annual growth rate).
- RSI (short-term signal)
- Whether recent price action is overheated or beaten down. Above 70 is overbought, below 30 oversold.
- MA20 / MA60 (moving averages)
- The 20- and 60-day average price. Price above them signals a firmer short-term trend.
- vs 52-week high
- How far below the past year's peak the price sits now (%).
All figures are for reference only; how they read varies by sector and over time.
Sources: Korea FSC market-price API (data.go.kr), OpenDART, KRX/KIND — public data only.
Bong Stocks presents public-data-based information for reference only. It is not investment advice and contains no target prices, ratings, or buy/sell recommendations. Verify independently before making any decision.